secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001493152-25-019748
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA enrolls first five patients in THIO-101 Part C expansion in Taiwan and Turkey
--------------------------------------------------------------------------------

- Presented trial-in-progress poster on ateganosine (THIO) plus ICI for advanced NSCLC at AACR-NCI-EORTC conference, Oct 22-26, 2025 in Boston.
- Enrolled first five patients in Part C (expansion) of THIO-101 Phase 2 trial from Taiwan and Turkey.
- Trial evaluates ateganosine (THIO) followed by cemiplimab in 3L NSCLC patients resistant to prior checkpoint inhibitor and chemo.
- Screening ongoing in Europe and Asia with multi-continental sites; safety profile aligned with earlier parts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225019748/0001493152-25-019748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225019748/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer